Stoke Therapeutics Net Income
| STOK Stock | USD 32.40 1.92 6.30% |
As of the 8th of February, Stoke Therapeutics has the Semi Deviation of 3.54, risk adjusted performance of 0.085, and Coefficient Of Variation of 1048.33. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Stoke Therapeutics, as well as the relationship between them.
Stoke Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.8034 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -80.1 M | -84.1 M | |
| Net Loss | -91 M | -86.4 M | |
| Net Loss | -80.1 M | -84.1 M | |
| Net Loss | (1.89) | (1.99) |
Stoke | Net Income | Build AI portfolio with Stoke Stock |
Historical Net Income data for Stoke Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Stoke Therapeutics represents a compelling investment opportunity.
Latest Stoke Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Stoke Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Stoke Therapeutics financial statement analysis. It represents the amount of money remaining after all of Stoke Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Stoke Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Stoke Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (88.98 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Stoke Net Income Regression Statistics
| Arithmetic Mean | (39,517,114) | |
| Coefficient Of Variation | (100.91) | |
| Mean Deviation | 36,430,840 | |
| Median | (12,521,000) | |
| Standard Deviation | 39,875,263 | |
| Sample Variance | 1590T | |
| Range | 99.1M | |
| R-Value | (0.88) | |
| Mean Square Error | 371.7T | |
| R-Squared | 0.78 | |
| Slope | (6,977,668) | |
| Total Sum of Squares | 25440.6T |
Stoke Net Income History
Other Fundumenentals of Stoke Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Stoke Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Stoke Therapeutics is extremely important. It helps to project a fair market value of Stoke Stock properly, considering its historical fundamentals such as Net Income. Since Stoke Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Stoke Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Stoke Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.68 | Revenue Per Share | Quarterly Revenue Growth 1.172 | Return On Assets | Return On Equity |
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Stoke Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Stoke Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Stoke Therapeutics.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Stoke Therapeutics on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Stoke Therapeutics or generate 0.0% return on investment in Stoke Therapeutics over 90 days. Stoke Therapeutics is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines t... More
Stoke Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Stoke Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Stoke Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.87 | |||
| Information Ratio | 0.0752 | |||
| Maximum Drawdown | 22.69 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 8.2 |
Stoke Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Stoke Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Stoke Therapeutics' standard deviation. In reality, there are many statistical measures that can use Stoke Therapeutics historical prices to predict the future Stoke Therapeutics' volatility.| Risk Adjusted Performance | 0.085 | |||
| Jensen Alpha | 0.3394 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.0866 | |||
| Treynor Ratio | 0.4391 |
Stoke Therapeutics February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.085 | |||
| Market Risk Adjusted Performance | 0.4491 | |||
| Mean Deviation | 3.34 | |||
| Semi Deviation | 3.54 | |||
| Downside Deviation | 3.87 | |||
| Coefficient Of Variation | 1048.33 | |||
| Standard Deviation | 4.45 | |||
| Variance | 19.81 | |||
| Information Ratio | 0.0752 | |||
| Jensen Alpha | 0.3394 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.0866 | |||
| Treynor Ratio | 0.4391 | |||
| Maximum Drawdown | 22.69 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 8.2 | |||
| Downside Variance | 14.98 | |||
| Semi Variance | 12.52 | |||
| Expected Short fall | (3.83) | |||
| Skewness | 0.355 | |||
| Kurtosis | 0.8426 |
Stoke Therapeutics Backtested Returns
Stoke Therapeutics appears to be not too volatile, given 3 months investment horizon. Stoke Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.16, which indicates the firm had a 0.16 % return per unit of risk over the last 3 months. By inspecting Stoke Therapeutics' technical indicators, you can evaluate if the expected return of 0.69% is justified by implied risk. Please review Stoke Therapeutics' Semi Deviation of 3.54, coefficient of variation of 1048.33, and Risk Adjusted Performance of 0.085 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Stoke Therapeutics holds a performance score of 12. The entity has a beta of 0.94, which indicates possible diversification benefits within a given portfolio. Stoke Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Stoke Therapeutics is expected to follow. Please check Stoke Therapeutics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Stoke Therapeutics' existing price patterns will revert.
Auto-correlation | -0.28 |
Weak reverse predictability
Stoke Therapeutics has weak reverse predictability. Overlapping area represents the amount of predictability between Stoke Therapeutics time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Stoke Therapeutics price movement. The serial correlation of -0.28 indicates that nearly 28.0% of current Stoke Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.28 | |
| Spearman Rank Test | -0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 3.11 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Stoke Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Stoke Therapeutics reported net income of (88.98 Million). This is 126.07% lower than that of the Biotechnology sector and 227.03% lower than that of the Health Care industry. The net income for all United States stocks is 115.58% higher than that of the company.
Stoke Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stoke Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Stoke Therapeutics could also be used in its relative valuation, which is a method of valuing Stoke Therapeutics by comparing valuation metrics of similar companies.Stoke Therapeutics is currently under evaluation in net income category among its peers.
Stoke Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Stoke Therapeutics from analyzing Stoke Therapeutics' financial statements. These drivers represent accounts that assess Stoke Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Stoke Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 881.4M | 359.0M | 231.4M | 595.7M | 685.1M | 804.8M | |
| Enterprise Value | 738.0M | 247.8M | 42.0M | 470.1M | 540.6M | 642.2M |
Stoke Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Stoke Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Stoke Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Stoke Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Stoke Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Stoke Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Stoke Therapeutics' value.| Shares | State Street Corp | 2025-06-30 | 1.5 M | Goldman Sachs Group Inc | 2025-06-30 | 1.3 M | Geode Capital Management, Llc | 2025-06-30 | 972.9 K | Polar Capital Holdings Plc | 2025-06-30 | 883.6 K | Mpm Oncology Impact Management Lp | 2025-06-30 | 789.7 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 673.9 K | Ci Private Wealth Llc | 2025-06-30 | 659.8 K | Opaleye Management Inc | 2025-06-30 | 562.1 K | Bank Of America Corp | 2025-06-30 | 548.1 K | Fmr Inc | 2025-06-30 | 7.4 M | Blackrock Inc | 2025-06-30 | 5.9 M |
Stoke Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.052 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | (4.05) % | ||||
| Current Valuation | 1.6 B | ||||
| Shares Outstanding | 57.12 M | ||||
| Shares Owned By Insiders | 4.00 % | ||||
| Shares Owned By Institutions | 96.00 % | ||||
| Number Of Shares Shorted | 11.15 M | ||||
| Price To Book | 6.00 X | ||||
| Price To Sales | 9.00 X | ||||
| Revenue | 36.55 M | ||||
| Gross Profit | 205.63 M | ||||
| EBITDA | (99.19 M) | ||||
| Net Income | (88.98 M) | ||||
| Cash And Equivalents | 275.63 M | ||||
| Cash Per Share | 6.99 X | ||||
| Total Debt | 2.32 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 10.46 X | ||||
| Book Value Per Share | 5.59 X | ||||
| Cash Flow From Operations | (86.85 M) | ||||
| Short Ratio | 13.37 X | ||||
| Earnings Per Share | 0.68 X | ||||
| Price To Earnings To Growth | 0.27 X | ||||
| Target Price | 41.89 | ||||
| Number Of Employees | 128 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 1.85 B | ||||
| Total Asset | 271.56 M | ||||
| Retained Earnings | (490.83 M) | ||||
| Working Capital | 192.7 M | ||||
| Net Asset | 271.56 M |
About Stoke Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stoke Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stoke Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stoke Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.68 | Revenue Per Share | Quarterly Revenue Growth 1.172 | Return On Assets | Return On Equity |
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.